Blanchette Rockefeller Neurosciences Institute

Cognitive Research Enterprises, Inc.

The United States of America As Represented by the Department of Health

Synaptogenix, Inc.

Other

West Virginia University

Environmental Research Institute of Michigan

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America

Erim International, Inc.

Neurodiagnostics LLC

US Government As Represented by the Secretary of the Army

Neurogx LLC

Alkon, Daniel L.

Khan, Tapan, Kumar

Daniel L Alkon

Thomas J Nelson

Thomas P Vogl

Tapan Kumar Khan

Rene Etcheberrigaray

Alessandro Quattrone

Miao-Kun Sun

Florin Valentin Chirila

Thomas E Nelson

Kim T Blackwell

Wei-Qin Zhao

Kim L Blackwell

Garth S Barbour

Christopher S Kim

Tom J Nelson

Yi-Fan Han

Florin V Chirila

Gary E Gibson

Maurizio Grimaldi

Lipo Wang

Antonelle R Favit

Etsuro Ito

Ofer Zohar

Jarin Hongpaisan

Jason Huber

Charles L Rosen

This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.

Lymphocyte-based morphometric test for alzheimer's disease

The present disclosure describes novel PKC-ε activators chosen from halogenated esters of unsaturated fatty acids and derivatives thereof, including halogenated esters of both polyunsaturated and monounsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.

Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases

Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecutive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.

Dosing regimens of PKC activators

The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.

PKC-activating compounds for the treatment of neurodegenerative diseases

The present disclosure describes novel PKC-&#x3b5; activators chosen from halogenated esters of unsaturated fatty acids and derivatives thereof, including halogenated esters of both polyunsaturated and monounsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.

Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.

The present disclosure relates to a peripheral diagnostic method for screening Alzheimer's disease in patients based on quantitatively measured complexity of skin-sampled fibroblast networks.

Peripheral diagnostic methods for screening Alzheimer's disease using beta amyloid and intercellular communication

A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.

Methods for inducing synaptogenesis with synaptic growth factor activating compounds

The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

PKC activators and combinations thereof

The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.

Compositions and methods to treat niemann-pick disease

Growing community of inventors

Bethesda, MD, United States of America

Daniel L Alkon